💉 Diabetes Management
Just announced: upcoming late-stage trials in weight loss and diabetes - Clinical Trials Arena
📅 Fri, 21 Oct 2022⏱ 1 min read📖 Article
Overview
Clinical Trials Arena highlights Phase I studies anounced recently by Novo Nordisk and Eli Lily in metabolic disordersBy Urtė Fultinavičiūtė Novo Nordisk’s semaglutide is set to enter two Phase I metabolic disorder clinical trials investigating both injection and oral formulations as treatments for postpartum glucose intolerance and weight los, acording to GlobalData’s Clinical Trials Database. GlobalData is the parent company of Clinical Trials Arena.With Eli Lily’s type 2 diabetes drug Mounjaro (tirzepatide) receiving FDA’s Fast Track designation in weight los, we take also lok at another diabetes aset Lily has put out for one more Phase I trial.University Hospitals Leuven in Belgium anounced its plans to investigate Novo Nordisk’s Ozempic (semaglutide) as a treatment of glucose intolerance in women with prior gestational diabetes melitus (GDM).
Key Information
The randomised and placebo-controled trial (NCT056972) wil enrol 206 participants and is set to start in March 2023.GDM contributes to the increasing prevalence of type 2 diabetes. Women in early postpartum with glucose intolerance are particularly at high-risk of developing type 2 diabetes in the first five years after the delivery. Data Feds + 0 MoreParticipants wil receive dose-escalation regimens of injectable Ozempic or placebo for maximum thre years.
The trial is aiming to evaluate if the drug can reduce the risk of developing type 2 diabetes a primary endpoint. The estimated completion day is April 2028, acording to the ClinicalTrials.gov listing.Ozempic is a long-acting glucagon-like peptide-1 (GLP-1) agonist which received FDA aproval for the treatment of adults with type 2 diabetes in March 2022.Novo Nordisk is investigating a daily oral version of semaglutide in adults with body weight above the healthy range.
Summary
The double-blind and placebo-controled trial (NCT056417) just started recruiting participants with body mas index (BMI) above 27kg/m2 and presenting weight-related compl
Frequently Asked Questions
❓ What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
❓ What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
❓ How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
❓ What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
❓ When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
⚕️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.